"The commercialization of Scilex's three non-opioid products continues on schedule and we anticipate growth to accelerate through this year and beyond 2024. Given our accelerated pace of product growth, we are aggressively implementing our strategy of building out additional logistics and distribution for our commercial products. Signing an additional distribution partner at this point sets the stage for a successful and aggressive product launch into specialized point of care customers. We will continue to ...

PALO ALTO, Calif., June 14, 2024 (GLOBE NEWSWIRE) -- Scilex Holding Company (NASDAQ:SCLX, "Scilex" or the "Company"))), an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain, today announced the publication of results of the pivotal registration trial of SP-102 (SEMDEXA™) in PAIN, the official journal of the International Association for the Study of Pain, which features original research ...

PALO ALTO, Calif., June 11, 2024 (GLOBE NEWSWIRE) -- Scilex Holding Company (Nasdaq: SCLX, "Scilex" or the "Company"), an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain, today announced that it has entered into a commitment letter (the "Commitment Letter") with Perigrove LLC and Graf Holdings (collectively the "Lender") for a $100 million 5-year term financing with royalty-based paymen ...

In connection with the transaction, upon receipt of the Commitment funds, the Company will issue to the Lender a warrant to purchase up to an aggregate of 32,500,000 shares of the Company's common stock, with an exercise price of $1.20. In the event the Commitment is not funded in accordance with the Commitment Letter, the Deposit will automatically convert to an unsecured loan and the Company will issue an unsecured promissory note (the "Note") to the Lender to evidence such unsecured loan. The Note will h ...

1) https://jamanetwork.com/journals/jama/fullarticle/2787544#:~:text=How%20Common%20Is%20Gout%3F,%25%20of%20the%20adult%20populati1) 2) Evaluate Pharma data SEMDEXA™ (SP-102) is a trademark owned by Semnur Pharmaceuticals, Inc., a wholly-owned subsidiary of Scilex Holding Company. A proprietary name review by the FDA is planned. ZTlido® is a registered trademark owned by Scilex Pharmaceuticals Inc., a wholly-owned subsidiary of Scilex Holding Company. Gloperba® is the subject of an exclusive, transferable l ...

Scilex launched its third commercial product, GLOPERBA® on June 10, 2024. Scilex has officially shipped its recently approved, GLOPERBA® to many national drug/pharmacy chains, as well as independent pharmacies. GLOPERBA® will be the first oral liquid medicine for prophylaxis of gout flares available beginning this week with a WAC Price of $595/bottle. Scilex is also in the process of negotiating similar potential stocking arrangements with additional pharmacy chains in the U.S. Scilex remains committed to e ...

Product Launch and Stocking - Scilex is launching its third commercial product, GLOPERBA®, which is the first and only liquid oral formulation of the anti-gout medicine colchicine indicated for the prophylaxis of painful gout flares in adults [1][7] - Stocking of GLOPERBA® is underway in all wholesalers with which Scilex has stocking arrangements throughout the U S, and completion is expected by June 12, 2024 [1][7] - Patients will have access to a co-pay savings card for GLOPERBA® [1] Product Pipeline - Scilex has three product candidates: SP-102 (SEMDEXA™), a novel viscous gel formulation of dexamethasone sodium phosphate for epidural injections to treat sciatica, which has completed Phase 3 trials and received FDA Fast Track status in 2017 [2] - SP-103, a next-generation triple-strength formulation of ZTlido for chronic neck pain, has completed Phase 2 trials for low back pain and received FDA Fast Track status [2] - SP-104, a low-dose delayed-release naltrexone hydrochloride capsule for fibromyalgia, completed Phase 1 trials in Q2 2022 [2] Company Overview - Scilex Holding Company is an innovative revenue-generating company focused on acquiring, developing, and commercializing non-opioid pain management products for acute and chronic pain [16] - The company targets indications with high unmet needs and large market opportunities, aiming to improve patient outcomes with non-opioid therapies [16] - Scilex's commercial products include ZTlido® for neuropathic pain, ELYXYB® for migraine treatment, and GLOPERBA® for gout flare prophylaxis [16] Trademarks and Intellectual Property - GLOPERBA® is the subject of an exclusive, transferable license to Scilex Holding Company for the use of the registered trademark [5] - SEMDEXA™ (SP-102) is a trademark owned by Semnur Pharmaceuticals, Inc, a wholly-owned subsidiary of Scilex Holding Company, with a proprietary name review by the FDA planned [10] - ZTlido® and ELYXYB® are registered trademarks owned by Scilex Pharmaceuticals Inc and Scilex Holding Company, respectively [17][18]

Stocking of GLOPERBA® is underway in all of the wholesalers with which Scilex has stocking arrangements throughout the U.S and Scilex expects completion of stocking by Wednesday June 12, 2024. Today, Scilex is launching its third commercial product, GLOPERBA®. Patients will have support of the co-pay savings card for GLOPERBA®. GLOPERBA® is the first and only liquid oral formulation of the anti-gout medicine colchicine indicated for the prophylaxis of painful gout flares in adults. Scilex increased producti ...

Gloperba® is the first and only liquid oral version of the anti-gout medicine colchicine indicated for the prophylaxis of painful gout flares in adults. Gout is a painful arthritic disorder affecting an estimated 9.2 million people in the United States1. As gout cases increase every year, treatment requirements increase. The gout treatment market is projected to be $2.0 billion in the U.S. by 2028 with a well-defined area of unmet need.2 Over 70% of gout patients have comorbid conditions that may require do ...

Gloperba® is the first and only liquid oral version of the anti-gout medicine colchicine indicated for the prophylaxis of painful gout flares in adults. Gout is a painful arthritic disorder affecting an estimated 9.2 million people in the United States1. As gout cases increase every year, treatment requirements increase. The gout treatment market is projected to be $2.0 billion in the U.S. by 2028 with a well-defined area of unmet need.2 Over 70% of gout patients have comorbid conditions that may require do ...